Replies to post #8254 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

I consider Biolex a serious competitor but not a threat to make GTC irrelevant.

So far, the programs that the two companies have undertaken have not crossed paths. Biolex’s lead program, an interferon-alpha called Locteron, is not in an area where GTC is focused. Nor is Biolex’s #2 program for a clot-lysing drug called BLX-155. In short, there ought to be more than enough business to go around.